Device Trial Radar · NCT05345444
Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)
Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Actual
Start
May 26, 2022
Primary completion
Apr 24, 2026
Study completion Aug 2027
Sponsor
- Lead sponsor
- Weill Medical College of Cornell UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 25, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Male only, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-site trial for 42 subjects with intermediate risk prostate cancer who undergo Irreversible Electroporation (IRE) followed by Magnetic Resonance guided Radiotherapy MRgRT. The investigators hypothesize that the combined therapy will feasible and be safe to perform with low morbidity. Ultimately, RTIRE may provide optimal treatment for intermediate risk prostate cancer patients.
Conditions
- Prostate Cancer
Interventions
IRE & MRgRTDevice
Subjects will undergo Irreversible electroporation(IRE) followed by Magnetic resonance guided radiotherapy (MRgRT)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Feasibility as measured by percentage of subjects assessed at 12 weeks post-IRETime frame: 12 weeks
- Feasibility as measured by percentage of subjects assessed at 6 weeks post-MRgRT within 1 yearTime frame: 6 weeks
- Proportion of patients who remain cancer-freeTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Weill Cornell Medicine
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.